Director Resignations, Appointments, and Private Placement Closure

Rani Therapeutics Holdings, Inc. filed an 8-K on October 22, 2025, announcing significant board changes and a completed private placement. Directors Andrew Farquharson and Maulik Nanavaty resigned effective upon the closing of a $125 million private placement. Abraham Bassan (Partner at Samsara BioCapital) and Dr. Vasudev Bailey (Founder of Anomaly Ventures) were appointed to the board, with Bassan chairing the Nominating Committee and Bailey chairing the Compensation Committee. The company closed a private placement of 42.6 million Class A shares and warrants for up to 207.4 million additional shares, significantly expanding its capital structure. Board compensation follows existing non-employee director policies, and new directors have standard indemnification agreements. The changes reflect strategic alignment with major investors Samsara BioCapital and Anomaly Ventures, who retain board nomination rights while maintaining at least 25% ownership of their acquired securities.